Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), is a heterogeneous and aggressive type of non-Hodgkin's lymphoma with a bleak prognosis. This study was designed to assess the value of EFS24 as an alternative clinical endpoint and identify prognosis-related factors in PTCL, NOS. Patients diagnosed with PTCL, NOS were retrospectively collected and slides were reviewed by two hematopathologists. EFS was defined as the time from diagnosis to the occurrence of disease progression after initial treatment, retreatment, or death. Subsequent overall survival (OS) was defined from EFS24 or time of progression, if it occurred within 24 months, to the last follow-up or death. 97 cases with complete follow-up were selected. Approximately 66 patients (68.04%) failed to achieve ES24, with the median OS of 12.17 months, and 5-year OS rate of 15.17%. While patients who reached EFS24 had a median OS of 60.57 months and a 5-year OS rate of 68.77%. Multivariate Cox analysis indicated that bone marrow involvement and elevated β2 Microglobulin (β2-MG) were associated with a poor prognosis. B symptoms, extranodal involvement more than one site, and a high Ki67 index were significant factors in predicting the failure of EFS24. EFS24 can help stratify the subsequent outcomes of PTCL, NOS. Patients who achieve EFS24 have a favorable prognosis, although it does not reach that of the general population. On the other hand, patients who do not achieve EFS24 have an extremely poor prognosis. Therefore, EFS24 can be used for patient risk stratification, patient counseling, and study design.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

  1. Armitage JO (2017) The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 92(7):706–715

    Article  PubMed  Google Scholar 

  2. Bellei M et al (2018) The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 103(7):1191–1197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chen H et al (2022) The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. Asia Pac J Clin Oncol 19(5):e202–e214

    PubMed  Google Scholar 

  4. Chen Z et al (2021) Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol 11:607145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Oluwasanjo A et al (2019) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Cancer Treat Res 176:83–98

    Article  CAS  PubMed  Google Scholar 

  6. Liang X et al (2021) Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. Medicine (Baltimore) 100(13):e25194

    Article  CAS  PubMed  Google Scholar 

  7. Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479

    Article  CAS  PubMed  Google Scholar 

  8. Went P et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472–2479

    Article  CAS  PubMed  Google Scholar 

  9. Weisenburger DD et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402–3408

    Article  CAS  PubMed  Google Scholar 

  10. Maurer MJ et al (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91(11):1096–1101

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wang Y et al (2022) MCL-027 prognostic role of event-free survival at 24 months (EFS24) in newly diagnosed mantle cell lymphoma (MCL). Clin Lymphoma Myeloma Leuk 22(Suppl 2):S394

    Article  MathSciNet  CAS  Google Scholar 

  12. Maurer MJ et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066–1073

    Article  PubMed  PubMed Central  Google Scholar 

  13. Maurer MJ et al (2017) International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol 35(36):4019–4026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wudhikarn K et al (2019) Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol 37(5):578–585

    Article  PubMed  Google Scholar 

  15. Yang Y et al (2021) Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia 35(6):1671–1682

    Article  CAS  PubMed  Google Scholar 

  16. Chen H et al (2020) Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Ann Hematol 99(12):2847–2857

    Article  PubMed  Google Scholar 

  17. Kim YR et al (2022) Predictive factors of event-free survival at 24 months in patients with peripheral T-cell lymphoma: A retrospective study. Cancer Res Treat 54(2):613–620

    Article  CAS  PubMed  Google Scholar 

  18. Provencio M et al (2017) Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish lymphoma oncology group. Cancer 123(19):3709–3716

    Article  PubMed  Google Scholar 

  19. Hapgood G et al (2016) evaluation of the risk of relapse in classical hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol 34(21):2493–2500

    Article  PubMed  Google Scholar 

  20. Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766–1771

    Article  CAS  PubMed  Google Scholar 

  21. Horwitz S et al (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33(3):288–298

    Article  CAS  PubMed  Google Scholar 

  22. Moskowitz AJ et al (2021) A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood 138(26):2828–2837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Horwitz SM et al (2018) Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888–898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Huen A et al (2020) Phase I/Ib study of tenalisib (RP6530), a dual PI3K δ/γ Inhibitor in patients with relapsed/refractory T-cell lymphoma. Cancers (Basel) 12(8):2293

  25. Ansell SM et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319

    Article  PubMed  Google Scholar 

  26. Barta SK et al (2019) Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk 19(6):356-364.e3

    Article  PubMed  PubMed Central  Google Scholar 

  27. Park SI et al (2019) The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 125(9):1507–1517

    Article  CAS  PubMed  Google Scholar 

  28. Maurer MJ et al (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91(2):179–184

    Article  CAS  PubMed  Google Scholar 

  29. Novak AJ et al (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 5(8):e346

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bachy E et al (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132(1):49–58

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Beijing Hope Run Special Fund of Cancer Foundation of China (LC2018L04).

Author information

Authors and Affiliations

  1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Zheng Cao, Xiaojun Wang, Xuemin Xue & Xiaoli Feng

Authors
  1. Zheng Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaojun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xuemin Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoli Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors approved the final manuscript, Zheng Cao analyzed the data and edited the manuscript, Xiaojun Wang and Xuemin Xue collected the patients and related clinical information, Xiaoli Feng provided guidance and revised this manuscript.

Corresponding author

Correspondence to Xiaoli Feng.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The all authors declare that they have no conflicts of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, Z., Wang, X., Xue, X. et al. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS. Ann Hematol 103, 869–883 (2024). https://doi.org/10.1007/s00277-023-05559-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05559-x

Keywords

Search

Navigation